Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & Administrative
Others
Ratios

Candel Therapeutics (CADL) Revenue (2020 - 2023)

Candel Therapeutics' Revenue history spans 4 years, with the latest figure at -$673000.0 for Q4 2023.

  • For Q4 2023, Revenue fell 2270.97% year-over-year to -$673000.0; the TTM value through Dec 2023 reached -$2.6 million, down 2192.74%, while the annual FY2024 figure was $2.1 million, 180.54% up from the prior year.
  • Revenue for Q4 2023 was -$673000.0 at Candel Therapeutics, down from -$669000.0 in the prior quarter.
  • Across five years, Revenue topped out at $31000.0 in Q3 2020 and bottomed at -$673000.0 in Q4 2023.
  • The 4-year median for Revenue is $31000.0 (2020), against an average of -$165000.0.
  • The largest annual shift saw Revenue soared 416.67% in 2022 before it plummeted 2270.97% in 2023.
  • A 4-year view of Revenue shows it stood at $31000.0 in 2020, then plummeted by 80.65% to $6000.0 in 2021, then skyrocketed by 416.67% to $31000.0 in 2022, then tumbled by 2270.97% to -$673000.0 in 2023.
  • Per Business Quant, the three most recent readings for CADL's Revenue are -$673000.0 (Q4 2023), -$669000.0 (Q3 2023), and -$644000.0 (Q2 2023).